Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. (Eastern Time) on January 24 to discuss its fourth-quarter results. Key executives, including CEO Joaquin Duato and CFO Joseph J. Wolk, will lead the call. Interested parties can join via the company’s website or by phone. A replay will be available until February 7. The results are anticipated to provide insights into the company’s performance, which is crucial for stakeholders and market analysts.
Johnson & Johnson (NYSE: JNJ) will attend the 41st Annual J.P. Morgan Healthcare Conference on January 9 at 12:45 p.m. ET in
Johnson & Johnson (NYSE: JNJ) announced that CEO Joaquin Duato will take on the additional role of Chairman, effective January 2023, succeeding Alex Gorsky who steps down after 30 years. Duato, with over three decades at J&J, is recognized for his leadership and commitment to stakeholder value. The transition highlights the company's succession planning, with Duato poised to guide J&J through pivotal times. Both Gorsky's contributions and Duato's vision indicate a strategic focus on healthcare innovation and inclusivity.
ABIOMED, Inc. (NASDAQ: ABMD) reported financial results for the quarter ending September 30, 2022, with revenues reaching $266 million, marking an 11% increase in constant currency. This growth reflects the seventh consecutive quarter of double-digit constant currency growth. U.S. product revenue also increased by 10% to $208 million. However, procedural volumes were affected in July due to physician vacations and labor shortages, which improved by August and September. The company celebrated significant innovation milestones and FDA approvals.
Johnson & Johnson (NYSE: JNJ) has announced the acquisition of Abiomed (NASDAQ: ABMD) for $380.00 per share, valuing the deal at approximately $16.6 billion. The acquisition aims to enhance Johnson & Johnson’s MedTech segment, particularly in the cardiovascular space, addressing significant health needs related to heart failure. The acquisition is expected to be accretive to adjusted earnings starting in 2024. Abiomed's innovative technologies and strong growth potential will complement Johnson & Johnson's existing portfolio, facilitating market expansion in high-growth cardiovascular sectors.
Johnson & Johnson (NYSE: JNJ) reported Q3 2022 sales of $23.8 billion, a 1.9% increase from Q3 2021. Earnings per share (EPS) rose 22.6% to $1.68, while adjusted EPS decreased 1.9% to $2.55. Operational sales grew 8.1%, driven by strong performances in the pharmaceutical sector, particularly from drugs like DARZALEX and TREMFYA. The company is maintaining its full-year guidance for adjusted operational sales and EPS, despite adverse currency impacts. The quarter also saw significant regulatory approvals and a new $5 billion share repurchase program.
Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 31st Annual Global Healthcare Conference on November 10, 2022. Executive Vice President Jennifer Taubert will represent the company during a session at 12:50 p.m. (Eastern Time) at the Terranea Resort in Rancho Palos Verdes, CA. Investors can access the event via an audio webcast on the Johnson & Johnson website, with a replay available approximately 48 hours post-event.
Johnson & Johnson (NYSE: JNJ) announced its new consumer health company name, Kenvue, marking a significant step in its planned separation. Kenvue, signifying 'knowledge' and 'view,' aims to provide innovative health solutions globally. With a revenue of $14.6 billion in 2021, Kenvue will operate across 100+ countries. CEO Thibaut Mongon emphasized Kenvue's commitment to everyday care, leveraging its rich portfolio of iconic brands like Tylenol and Neutrogena. The separation is expected to complete in 2023.
Johnson & Johnson has launched a new Research & Development (R&D) facility in the San Francisco Bay Area, expanding its presence and doubling its R&D workforce in the region. This 200,000 square-foot campus will foster collaboration across its divisions, focusing on innovative healthcare solutions, including gene therapies and data science integration. The site aims to achieve Silver LEED certification, reinforcing the company's commitment to sustainability. CEO Joaquin Duato emphasizes the potential for transformative healthcare advancements from this investment.
Johnson & Johnson (NYSE: JNJ) announced a $5 billion repurchase of its common stock, reflecting confidence in its business and outlook. CEO Joaquin Duato emphasized the company's strong cash flow and lowest net debt in five years, enabling investments in innovation and dividends. The repurchase program is discretionary and without a time limit, allowing flexibility. The company also reaffirmed its full-year 2022 sales growth guidance of 6.5% to 7.5% and earnings per share forecast of $10.65 to $10.75.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
